The CEO exercised deeply in-the-money options and sold nearly all the resulting shares in a single day, a pattern consistent with pre-planned 10b5-1 diversification rather than a bearish signal. However, the concentration on one date and involvement of both C-suite executives warrants monitoring the next 10-Q for any negative fundamental surprise. Given the $6.1B market cap and 0.10% magnitude, this is unlikely to move the stock meaningfully.
Price Chart
Executive Summary
Oruka Therapeutics CEO Lawrence Klein and COO Laura Sandler sold a combined $5.94M in open-market stock on September 1, 2026. While the CEO's sales are partly explained by cashless derivative exercises at $7.80 strike (pre-funded near 100% profit), the $5.84M CEO sale is large relative to market cap (0.1%). The net selling direction and C-suite participation merit attention, though the size is modest as a percentage of market cap (<0.1%), keeping the signal below the materiality threshold.
Key Financial Metrics
Key Facts
- CEO Lawrence Klein sold 75,000 shares total (6.6K + 4.8K + 63.6K) in open-market sales for ~$6.89M, all on 2026-09-01
- CEO also exercised two derivative tranches: 75,000 shares at $7.80 ($585K exercise) and 75,000 shares at $0 (non-cash award)
- COO Laura Sandler sold 5,000 shares total for ~$459K on 2026-09-01 after exercising 5,000 at $7.80 and 5,000 at $0
- Combined open-market sales: CEO $6.89M + COO $459K = $7.35M total; net cluster value after derivative exercises: $5.94M
- Derivative exercises were essentially cashless — sold most shares immediately to lock in $84+ per share profit
- Total open-market sales of $7.35M represent ~0.12% of Oruka's $6.1B market cap
- The cluster is concentrated in a single day (2026-09-01), suggesting coordinated execution of a pre-arranged plan
Financial Impact
CEO and COO insider sales totaling $5.94M net value on September 1, 2026 — 0.10% of $6.1B market cap
Risk Factors
- Insider selling cluster concentrated on one date suggests potential vesting or window-driven sales, not necessarily informed bearish view
- CEO sold 100% of exercised shares immediately, locking in profit — typical for option exercise patterns
- No recent company disclosures (earnings, trial data, guidance) in the cross-filing context to connect the sales to fundamental news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1788303680828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access